Patient-Assisted Compression - Impact on Image Quality and Workflow
Phase: NA
Conditions: Breast Cancer
Sponsor: GE Healthcare

 
 
Page 1 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
Clinical Study Protocol: 
Patient-Assisted Compression – Impact on Image Quality and Workflow 
(124.03-2017-GES-0002) 
Version: 1.0; 22/May/2017 
Sponsor: 
 
General Electric Company, acting through its GE Healthcare Business 
3000 N. Grandview Blvd 
Waukesha, WI 53188 
Sponsor Contact:  
Sara Lam, 
Clinical Affairs Project Manager 
Tel:  
 
1-262-548-2369 
E-mail:   
Sara.J.Lam@ge.com 
Medical Monitor:  
Ron von Jako, MD, PhD, Medical Director 
Tel:  
 
1-617-669-3200 
E-mail:   
Ron.VonJako@med.ge.com 
Investigational Product: Patient-Assisted Compression, Senographe Pristina Modality: Imaging, 
Women's Health 
FOR QUALIFIED INVESTIGATORS, STUDY STAFF, AND THEIR 
ETHICS COMMITTEE(S) ONLY 
CONFIDENTIALITY STATEMENT 
Information in this RESEARCH STUDY PROTOCOL is for investigators, site personnel involved with the 
study, ethics committee(s), and/or their authorized representative(s) except as required to obtain 
consent from study participants or as otherwise required by law. Once signed, the terms of the 
protocol are binding for all parties. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 3 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
Table of Contents 
Document and Version Control ...................................................................................................................... 5 
List of Abbreviations and Terms..................................................................................................................... 6 
Study Synopsis ................................................................................................................................................... 7 
Administrative Structure of Investigation .................................................................................................. 11 
1. Background and Justification ................................................................................................................ 12 
 
Screening Mammography and Patient-Assisted Compression ................................................................................ 12
 
Controls and Minimization of Bias ............................................................................................................................................. 12
2. Device/Product Description ................................................................................................................... 13 
 
Identity, Mechanism, and Function of Investigational Device.................................................................................... 13
 
Mammography Review Workstation ....................................................................................................................................... 14
 
Intended Use......................................................................................................................................................................................... 14
 
Comparator ........................................................................................................................................................................................... 14
 
Concomitant/Ancillary Administrations ................................................................................................................................. 14
 
Accountability ...................................................................................................................................................................................... 14
 
Anticipated Risks and Benefits .................................................................................................................................................... 15
3. Study Objectives and Endpoints ............................................................................................................ 15 
 
Purpose of the Study ........................................................................................................................................................................ 15
 
Study Endpoints .................................................................................................................................................................................. 16
 
Summary of Study Design ............................................................................................................................................................. 16
4. Study Design.............................................................................................................................................. 17
 
Study Population ................................................................................................................................................................................ 17
 
Number Subjects ................................................................................................................................................................................ 17
 
Protection of Vulnerable Subjects ............................................................................................................................................. 17
Eligibility Criteria ................................................................................................................................................................................. 17
 
Recruiting and Screening ............................................................................................................................................................... 18
 
Breast of Interest Randomization .............................................................................................................................................. 18
 
Criteria for Withdrawal/Discontinuation ............................................................................................................................... 18
5. Study Procedures ..................................................................................................................................... 19
 
Diagram of Procedures ................................................................................................................................................................... 19
 
Subject Preparation .......................................................................................................................................................................... 20
 
Description of Study Procedures ............................................................................................................................................... 20
 
Follow-up ................................................................................................................................................................................................ 21
6. Study Data Collection and Assessments ............................................................................................. 21 
 
Image Acquisition Data ................................................................................................................................................................... 21
 
Image Attribute Review Data ....................................................................................................................................................... 22
 
Safety Assessments .......................................................................................................................................................................... 22
7. Qualification and Training Plan ............................................................................................................. 23 
 
Staff Qualifications ............................................................................................................................................................................ 23
 
Training Plan for the Protocol and Research Product .................................................................................................... 23
8. Safety .......................................................................................................................................................... 23 
 
Anticipated Adverse Events .......................................................................................................................................................... 23
 
Adverse Event Definitions .............................................................................................................................................................. 24
 
Documentation of Safety Events ............................................................................................................................................... 24
 
Reporting of Safety Events and Device Deficiencies/Complaints ............................................................................ 25
 
Device Deficiencies/Complaints ................................................................................................................................................. 25
9. Ethical Conduct of the Study .................................................................................................................. 25
 
Ethics Committee ............................................................................................................................................................................... 26
 
Regulatory Agencies and Competent Authority(ies) ........................................................................................................ 26
 
Management of Protocol Modifications and Amendments ........................................................................................ 26

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 4 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
 
Participant Information and Informed Consent ................................................................................................................ 26
 
Early Termination of the Study .................................................................................................................................................... 27
10. Statistical Methods .................................................................................................................................. 27 
 
Statistical Hypothesis ....................................................................................................................................................................... 27
 
Sample Size Determination ........................................................................................................................................................... 27
 
Statistical Analysis ............................................................................................................................................................................. 27
 
Handling of Missing Data ............................................................................................................................................................... 28
 
Deviation(s) from the Original Statistical Methods ........................................................................................................... 28
11. Quality Assurance and Control .............................................................................................................. 28
 
Data Management ............................................................................................................................................................................ 28
12. Monitoring Plan ........................................................................................................................................ 29 
 
Confidentiality and Data Protection ......................................................................................................................................... 29
 
Publication Policy ............................................................................................................................................................................... 30
References ........................................................................................................................................................ 31
Appendix A – STUDY SCHEDULE .................................................................................................................... 33
Appendix B – Study Site and Investigator List ........................................................................................... 34 
List of Figures and Tables 
Figure 1 –Senographe Pristina mammography device with remote control for patient-assisted compression 
mode. ............................................................................................................................................................................................................................... 13 
Figure 2 – Schematic showing image acquisitions based on the randomly-assigned breast of interest (i.e. first or 
second breast). ............................................................................................................................................................................................................ 18 
Figure 3 – Diagram of study procedures. ..................................................................................................................................................... 19 
Table A.1 - Schedule of Study Procedures.................................................................................................................................................... 33 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
 
 
Page 5 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
DOCUMENT AND VERSION CONTROL 
This section records all changes made to the protocol for a specific study. In the table below, record every 
relevant change by indicating what changes were made. 
Revision 
Date 
Revision Author 
Comments/Changes 
1.0 
22/May/2017 
Carrie Lauer 
Clinical Writer – This is the initial version. 
 
 
 
 
 
 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
 
 
Page 6 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
LIST OF ABBREVIATIONS AND TERMS 
2D 
Two dimensional 
3D  
Three dimensional 
AE 
Adverse Event 
ADE 
Adverse Device Effect 
ALARP As Low as Reasonably Practicable 
CA 
Competent Authority 
CAPM 
GE Clinical Affairs Project Manager 
CC 
Craniocaudal 
CCG 
Case Report Form Completion Guidelines 
CFR 
Code of Federal Regulations 
CHF 
Clinical History File (synonymous with e-Trial Master File) 
CRF 
Case Report Form 
DBT 
Digital Breast Tomosynthesis 
DCF 
Data Clarification Form 
EC 
Ethics Committee 
EU 
European Union 
FDA 
United States Food and Drug Administration 
FFDM 
Full-field Digital Mammography 
GCP 
Good Clinical Practice (see ISO 14155:2011) 1 
GE 
General Electric 
GEHC 
General Electric Healthcare 
Guidance   Guidance for Industry and FDA Staff - Class II Special Controls Guidance Document: Full-Field Digital  
 
     Mammography System (2012) 
ICF 
Informed Consent Form 
ISO 
International Standards Organization 
MLO 
Mediolateral Oblique 
MQSA     Mammography Quality Standards Act 
MWS 
GE MyWorkshop Internal Documentation System 
PA 
Patient-assisted 
PI 
Principal Investigator 
Reader Interpreting Physician, as defined under U.S. FDA 21CFR §900.12(a)(1)(i)(B)(2) 
SADE 
Serious Adverse Device Effect 
SAE 
Serious Adverse Event 
TC 
Technologist-controlled 
US 
United States 
USADE Unexpected Serious Adverse Device Effect 
 
 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
 
 
Page 7 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
STUDY SYNOPSIS 
 
Sponsor: 
General Electric Company, acting through its GE Healthcare Business 
Research Type: 
This is a Clinical, single-blind, randomized, prospective research study. 
Regulatory Status: 
This is a pre-market research study of the following products: 
Pre-market:  
Patient-assisted compression on Senographe Pristina 
Post-market:  
Technologist-controlled compression on Senographe Pristina 
Background and 
Rationale: 
Patient-assisted compression allows the patient to participate in controlling the 
amount of compression force during mammography and is a personalized 
approach that has demonstrated successful reduction in discomfort experienced 
during mammography. GE Healthcare’s Senographe Pristina, an innovative 
mammography platform that provides both two-dimensional (2D) and three-
dimensional (3D) imaging capabilities, offers both standard and patient-assisted 
compression modes. This study is being conducted to compare the image quality of 
breast images obtained using standard compression and patient-assisted (PA) 
compression, and to evaluate the impact of patient-assisted compression on clinical 
workflow. Results from this study are intended to support regulatory submissions. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
 
 
Page 8 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
Procedures/ 
Methods: 
The study population will consist of adult asymptomatic women presenting for 
screening 2D mammography. One breast of each subject will be identified as the 
“breast of interest,” which will undergo two-view (craniocaudal and mediolateral 
oblique) PA compression and image acquisition, immediately followed by 
technologist-controlled (TC) compression and image acquisition. The breast of 
interest will be randomly assigned to either the first breast imaged during the exam 
or the second breast imaged. TC compression and imaging, and procedures 
performed on the subject’s other breast will be conducted per standard of care.  
Following image acquisition, image quality evaluation will be conducted by MQSA-
qualified readers. Prior to the reading session, images will be de-identified and the 
following information will be removed from the DICOM header to blind readers to the 
compression mode used during acquisition: time stamp, compression force, and 
breast thickness. Two (2) readers will evaluate each PA and TC compression image 
set collected from each subject’s breast of interest and assess the acceptability of 
image attributes, as defined in the Guidance for Industry and FDA Staff - Class II 
Special Controls Guidance Document: Full-Field Digital Mammography System (2012). 
A third reader will provide adjudication, if there is disagreement for a given image 
set’s overall clinical image quality.  
Workflow data, including time to complete image acquisition for each compression 
mode and the incidence of technologist intervention during acquisition, will also be 
collected. 
The proportion of PA image sets that are of equal or higher acceptability than TC 
image sets will be calculated.  A 95% confidence interval will be calculated using 
asymptotic method with continuity correction. The proportion of image sets 
indicated for repeated image acquisition when using PA mode or TC mode will be 
summarized. Other endpoint data will be summarized using descriptive statistics. No 
statistical hypothesis is being tested in this study.  
Objectives: 
The primary objective is to compare the acceptability of overall image quality in 
unilateral two-view (CC and MLO) breast images acquired using PA and TC 
compression modes. 
The secondary objectives are: 
• 
To evaluate the need for repeat image acquisition when using PA and TC 
compression modes; and 
• 
To evaluate acceptability of mammographic attributes for unilateral two-
view breast images acquired using PA and TC compression modes, per the 
Guidance for Industry and FDA Staff - Class II Special Controls Guidance 
Document: Full-Field Digital Mammography System (2012; hereafter referred 
to as the “Guidance”). 
The exploratory objectives are: 
• 
To collect workflow data for PA compression and TC compression, and 
• 
To collect breast thickness, radiation dose, and compression force for 
images acquired using PA and TC compression. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
 
 
Page 9 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
Endpoints: 
 
The primary endpoint is the overall image quality acceptability on a per subject-
basis using a binary response of either acceptable or unacceptable for unilateral, 
two-view PA and TC compression image sets. 
The secondary endpoints are: 
• 
Number of incidences per image set when the technologist and/or readers 
indicate a repeat acquisition for PA and TC compression; and 
• 
Acceptability of mammographic attributes, as defined in the Guidance and 
as described in Section 6.2 Image Attribute Review Data. 
The exploratory endpoints will be collected per subject for each study-specific PA 
and TC compression. The endpoints are: 
• 
Time to complete image acquisition; 
• 
Type and incidence of technologist interventions (e.g. technologist uses 
footswitch to increase compression); and 
• 
Breast thickness, radiation dose, and compression force. 
The safety endpoints are the type and number of AEs, SAEs, and device issues 
Eligibility criteria: 
 
Inclusion criteria: 
1) Are women aged 40 years or older;  
2) Are asymptomatic and scheduled 
for FFDM screening 
mammography; 
3) Have left and right breasts; 
4) Have breast sizes compatible with 
the dimensions of a 24 x 31 cm 
image detector, without 
anatomical cut-off; 
5) Are documented as non-pregnant 
based on the investigator’s 
medical judgment and in 
consideration of local clinical 
practice standards for evidence of 
non-pregnancy;  
6) Are able and willing to comply with 
study procedures; and 
7) Are able and willing to provide 
written informed consent to 
participate. 
Exclusion criteria: 
1) Have been previously included in this 
study or are participating in another 
study expected to interfere with 
study procedures or outcomes; 
2) Have undergone diagnostic or 
surgical intervention(s) or 
procedure(s) on either breast, 
including breast biopsy, 
lumpectomy, or reconstruction, 
within five (5) years (≤ 5 years) of the 
study exam date;  
3) Are currently undergoing 
radiotherapy or chemotherapy, or 
have a history of prior radiotherapy 
treatment on either breast; 
4) Are currently lactating; or 
5) Have breast implants. 
 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
 
 
Page 10 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
Sample size and Sites: 
Up to 36 subjects from one (1) site will be included as part of this study to achieve 
the targeted number of complete and evaluable subjects. The target sample size for 
this study is 30 subjects, providing 60 evaluable image sets for the image attribute 
review (30 PA compression image sets and 30 TC compression image sets). The 
number of subjects was determined based on Sponsor discussions with a U.S. FDA 
Medical Officer, who indicated that, during MQSA re-accreditation, sites are 
requested to submit sample images. If an issue is identified with the sample images, 
an Advanced Mammographic Review occurs, where the quality of 30 images is 
assessed to determine whether the issue was isolated or systemic. 
Study duration: 
The study is expected to last approximately three (3) months. 
 
 
 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
 
 
Page 11 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
ADMINISTRATIVE STRUCTURE OF INVESTIGATION 
Clinical 
Affairs 
Project Manager 
(Sponsor Contact):  
Sara Lam 
Tel:  
1-262-548-2369 
e-mail:  
Sara.J.Lam@ge.com 
GE Healthcare (GEHC) 
Address:  3000 N Grandview Blvd 
Waukesha, WI 53188 U.S. 
Research Manager:  
 
Sandhya Parameswaran  
Tel:  
1-262-951-8169 
e-mail:  
Sandhya.Parameswaran@med.ge.com  
GEHC  
Address: 3000 N Grandview Blvd 
 
Waukesha, WI 53188 U.S. 
Medical Monitor:  
 
Ron von Jako, MD, PhD 
Tel:  
1-617-669-3200 
e-mail:  
Ron.VonJako@med.ge.com 
GEHC  
Address:  1100 Technology Park Drive  
 
Billerica,  MA 01821 U.S. 
Biostatistician: 
Keyi Wang 
Tel:  
1-262-548-2945 
e-mail:  
Keyi.Wang@ge.com 
GEHC 
Address: 3000 N Grandview Blvd 
 
Waukesha, WI 53188 U.S. 
 
 
 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 12 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
1. BACKGROUND AND JUSTIFICATION 
 Screening Mammography and Patient-Assisted Compression 
Leading authorities on breast cancer recommend regular screening mammography for women aged 40 years 
and older as a means of early detection for breast cancer, leading to increased survival rates and more treatment 
options. 2, 3, 4 Numerous randomized trials have demonstrated that regular mammographic screening reduces 
breast cancer mortality, 5, 6, 7, 8, 9  with more than 40% reduction in breast cancer deaths. 10, 11  Amidst the success 
of screening mammography, clinicians struggle to maintain patient participation in regular screening programs. 
Notably, a systematic review by Whelehan, et al. concluded that pain experienced during screening 
mammography (e.g. compression pain) contributed to reduced rates of repeat participation in regular screening 
programs. 12  
Adequate breast compression during mammography creates uniform thickness and flattens tissues, 4 which is 
necessary to obtain sufficient image quality 4, 13, 14 and reduce radiation dose. 4, 15  Various methods are being 
investigated to maintain sufficient compression while reducing pain associated with mammography. Specifically, 
studies have shown that a personalized approach to compression can significantly reduce pain intensity and 
discomfort experienced by patients while maintaining diagnostic image quality. 16, 17, 18 
Patient-controlled compression allows the patient to control the amount of compression force during 
mammography and is a personalized approach that has demonstrated successful pain reduction in 
mammography. 16 GE Healthcare’s Senographe Pristina, an innovative mammography platform that provides 
both two-dimensional (2D) and three-dimensional (3D) imaging capabilities, offers standard and patient-assisted 
compression modes. The study described herein is being conducted to compare the image quality of breast 
images obtained using standard compression and patient-assisted compression in an asymptomatic female 
population undergoing full-field digital (FFDM) 2D screening mammography. This study will also evaluate the 
impact of patient-assisted compression on clinical workflow. Results from this study are intended to support 
regulatory submissions. 
 Controls and Minimization of Bias 
Due to the inherent difference in utility of standard and patient-assisted compression modes, study subjects and 
study staff will not be blinded to the compression mode. However, the following bias control methods will be 
employed in this study:  
• 
Selection bias will be limited by consecutively enrolling eligible subjects. 
• 
Spectrum bias will be limited by using a population expected to represent the general population at the 
investigational site, without regard to race or ethnicity. 
• 
Patient-assisted compression will be randomly assigned to either the first or second breast imaged to 
mitigate subject-learning bias associated with the amount of compression required for image 
acquisition. 
• 
Readers conducting image quality evaluations will be blinded to the compression mode used to obtain 
the images. 
• 
A minimum of three (3) radiology technologists will conduct the study procedures to mitigate bias 
introduced by technologist-specific practices. 
 
 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 13 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
2. DEVICE/PRODUCT DESCRIPTION 
 Identity, Mechanism, and Function of Investigational Device 
Name:  
Patient-Assisted Compression, Senographe Pristina  
Modality/Type: 
Imaging, Women's Health  
Manufacturer:  
GE 
Software version: 
Senographe Pristina 1.0, Axis version 1.50 
Regulatory Status:  Pre-market 
Note: A record of number of products issued, along with applicable identification numbers (e.g. serial/lot/batch) and 
components/accessories used in this study will be retained by the Sponsor as part of the clinical history file (CHF), 
as required by applicable laws and regulations. 
Patient-Assisted Compression, Senographe Pristina (Figure 1) is a commercial mammography medical device 
consisting of the Senographe Pristina FFDM system (2D) and Senographe Pristina DBT option (3D). The platform 
is an evolution of the cleared/approved Senographe Essential FFDM system (2D) and SenoClaire DBT option (3D). 
Senographe Pristina includes the same clinical applications as traditional mammography systems and is 
designed to improve workflow while maintaining imaging capabilities and image quality of FFDM and DBT breast 
imaging. The FFDM option will be used for the purposes of this study. 
Senographe Pristina includes the hardware and software components required for multi-modality functioning 
and is designed to improve patient experience, patient throughput, and radiographer experience. The system 
offers two compression modes – standard mode and the optional patient-assisted compression mode (referred 
to as “PA compression” hereafter). The patient-assisted feature enables the patient to personally refine breast 
compression using a hand-held remote control (Figure 1) after the compression has been initiated by the 
operator, which is required to ensure proper breast positioning.  
 
Figure 1 –Senographe Pristina mammography device with remote control for patient-assisted compression mode. 
The research device (i.e. Senographe Pristina with PA compression), instructions for use, or packaging shall 
indicate that the research device is for use in a research investigation, in accordance with applicable regulations 
in the U.S., including U.S. FDA 21 CFR and other applicable laws and regulations. Senographe Pristina with PA 
compression will be exclusively used for research purposes. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 14 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
The results of this study are intended to support regulatory submissions for PA compression. Results may be used 
to help commercialize the product in other global regions in the future, at the discretion of the Sponsor. 
 Mammography Review Workstation 
An FDA-cleared mammography review workstation or other image review system will be used in this study to 
display images during reader evaluations of the image sets. Review workstations/systems are not a component 
of Senographe Pristina.  
The study-specific images will be labelled for research use only, and the investigational image sets will be 
exclusively used for research purposes. 
Intended Use
Senographe Pristina is intended to be used for screening and diagnostic mammography; however, screening 
mammography is the focus of this study. Study procedures are intended for research purposes and are not 
intended as a substitute for required medical care. 
 Comparator 
The comparator is the technologist-controlled compression mode of Senographe Pristina (referred to as “TC 
compression” hereafter). This is considered the “standard” compression mode, which is currently cleared for use 
with Senographe Pristina. 
 Concomitant/Ancillary Administrations 
 Medications and Biologic Products 
No medications or biologic products will be administered as part of study procedures. 
 Laboratory Tests and Sample Processing 
No laboratory tests or sample processing is planned as part of the study procedures. 
 Accountability 
Accurate and adequate records will be maintained for all devices/products, from time of shipment to the site 
until return or disposal of all devices issued by the Sponsor as part of this study, as required by applicable laws 
and regulations. The Principal Investigator (PI) will be ultimately responsible for the security and integrity of 
research devices/products at the investigational site during the study. 
 Issuance 
The PA compression product will be provided by the Sponsor while the Senographe Pristina and the review 
workstations will be provided by the site. Calibration/maintenance of study product(s) is not planned to maintain 
integrity of study data. 
 Disposition 
Product(s) provided to the site by the Sponsor will be returned to the Sponsor, in accordance with applicable laws 
and regulations.  

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 15 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
 Anticipated Risks and Benefits 
The device under study has undergone risk assessment, in accordance with International Standards 
Organization (ISO) 14971:2012. Risks have been mitigated to levels as low as reasonably possible (ALARP) and 
are not expected to exceed risks associated with the routine clinical breast cancer screening procedures that 
the subject has been prescribed outside of the study. The operator’s manual highlights warnings, cautions, and 
potential conventional risks associated with the exam. 
Breast imaging procedures will be conducted using post-market Senographe Pristina systems with pre-market 
PA compression mode installed. Breast imaging procedures will be conducted per the site’s standard of care, 
with the exception of the investigational imaging, which will consist of unilateral two-view (craniocaudal [CC] and 
mediolateral oblique [MLO]) imaging acquired using the PA compression. There will be no repeat imaging 
administered using PA compression mode.  
No additional medications will be administered beyond those regularly required for the subject’s medical care 
outside of this study, and regular medication should not be adversely impacted or delayed by study participation. 
Post-trial care and follow-up are not required by this study. 
There is no expected benefit to study subjects participating in this research. The results of this study may benefit 
future patients by increasing knowledge about the PA compression mode of Senographe Pristina. 
 Risk Category and Rationale 
The Senographe Pristina FFDM system with PA compression mode, as used in this study, is not considered a 
significant risk device per the 21 CFR §812.3 definition:  
1) it is not intended as an implant;  
2) is not purported or represented to be for a use in supporting or sustaining human life;  
3) is not for a use of substantial importance in diagnosing, curing, mitigating, or treating disease, or 
otherwise preventing impairment of human health; and 
4) it does not otherwise present a potential for serious risk to the health, safety, or welfare of a subject. 
This designation of non-significant risk is supported by the study design, in which the data obtained will not be 
used as the sole measure of diagnosis without distinct confirmation from conventional methods, such as 
mammography on an approved/cleared device or other standard of care procedures at the investigational site. 
3. STUDY OBJECTIVES AND ENDPOINTS 
 Purpose of the Study 
The purpose of this study is to collect clinical evidence associated with image quality and workflow to support 
regulatory submissions for Senographe Pristina PA compression mode. 
 Primary Objective 
The primary objective is to compare the acceptability of overall image quality in unilateral two-view (CC and MLO) 
breast images acquired using PA and TC compression modes. 
 Secondary Objectives 
The secondary objectives are: 
• 
To evaluate the need for repeat image acquisition when using PA and TC compression modes; and 
• 
To evaluate acceptability of mammographic attributes for unilateral two-view breast images acquired 
using PA and TC compression modes, per the Guidance for Industry and FDA Staff - Class II Special 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 16 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
Controls Guidance Document: Full-Field Digital Mammography System (2012; hereafter referred to as the 
“Guidance”). 
 Exploratory Objectives 
The exploratory objectives are: 
• 
To collect workflow data for PA compression and TC compression, and 
• 
To collect breast thickness, radiation dose, and compression force for images acquired using PA and TC 
compression. 
 Safety Objective 
The objective is to collect safety information, including adverse events (AEs), serious adverse events (SAEs), and 
product issues. 
Study Endpoints
 Primary Endpoint 
The primary endpoint is the overall image quality acceptability on a per subject-basis using a binary response of 
either acceptable or unacceptable for unilateral, two-view PA and TC compression image sets. 
 Secondary Endpoints  
The secondary endpoints are: 
• 
Number of incidences per image set when the technologist and/or readers indicate a repeat acquisition 
for PA and TC compression; and 
• 
Acceptability of mammographic attributes, as defined in the Guidance and as described in Section 6.2 
Image Attribute Review Data. 
 Exploratory Endpoints 
The exploratory endpoints will be collected per subject for each study-specific PA and TC compression. The 
endpoints are: 
• 
Time to complete image acquisition; 
• 
Type and incidence of technologist interventions (e.g. technologist uses footswitch to increase 
compression); and 
• 
Breast thickness, radiation dose, and compression force. 
 Safety Endpoints 
The safety endpoints are the type and number of AEs, SAEs, and device issues. 
 Summary of Study Design 
This is a pre-market, Clinical, single-blind, prospective, randomized research study conducted at one (1) site in 
the U.S. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 17 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
4. STUDY DESIGN 
 Study Population 
The study population will consist of asymptomatic adult women presenting for screening FFDM breast imaging, 
which is representative of the general population expected to use Senographe Pristina in clinical practice. 
 Number Subjects 
Up to 36 subjects will be enrolled into this study at one (1) site to achieve the targeted number of 30 complete 
and evaluable subjects. 
 Protection of Vulnerable Subjects 
Vulnerable subjects are individuals whose willingness to volunteer in a clinical investigation could be unduly 
influenced by the expectation, whether justified or not, of benefits associated with participation or of retaliatory 
response from senior members of a hierarchy in case of refusal to participate.  
The Sponsor shall avoid improper influence on, or inducement of, the subject, monitor, any investigator(s), or 
other parties participating in, or contributing to, the clinical investigation. 
All investigators shall avoid improper influence on, or inducement of, the subject, Sponsor, monitor, other 
investigator(s), or other parties participating in, or contributing to, the clinical investigation. 
This study does not examine any groups of subjects who are considered to be vulnerable subjects in the country 
in which the study is being conducted. 
 Eligibility Criteria  
 Inclusion Criteria  
Subjects who meet all the following inclusion criteria may be included: 
1) Are women aged 40 years or older;  
2) Are asymptomatic and scheduled for FFDM screening mammography; 
3) Have left and right breasts; 
4) Have breast sizes compatible with the dimensions of a 24 x 31 cm image detector, without anatomical 
cut-off; 
5) Are documented as non-pregnant based on the investigator’s medical judgment and in consideration 
of local clinical practice standards for evidence of non-pregnancy;  
6) Are able and willing to comply with study procedures; and 
7) Are able and willing to provide written informed consent to participate. 
 Exclusion Criteria  
1) Have been previously included in this study or are participating in another study expected to interfere 
with study procedures or outcomes; 
2) Have undergone diagnostic or surgical intervention(s) or procedure(s) on either breast, including breast 
biopsy, lumpectomy, or reconstruction, within five (5) years (≤ 5 years) of the study exam date;  

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 18 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
3) Are currently undergoing radiotherapy or chemotherapy, or have a history of prior radiotherapy 
treatment on either breast; 
4) Are currently lactating; or 
5) Have breast implants. 
 Recruiting and Screening  
Subjects will be recruited for potential enrollment into this study from an adult asymptomatic female population 
scheduled for screening FFDM at the site. Subjects will be screened for enrollment against the inclusion and 
exclusion criteria, and enrollment determinations will be made by the PI. Recruitment, screening, and enrollment 
will be conducted per the standard procedures of the investigational site. All subject participation will be 
voluntary. 
Following recruitment, a subject will be considered enrolled (the point of enrollment) once she signs and dates 
the informed consent form (ICF). Once enrolled, the subject will be assigned a unique subject number, which will 
not contain information that could identify her (e.g. subject name or date of birth). The unique subject number 
will be used to label case report form (CRF) data for the subject throughout her participation in the study. 
 Breast of Interest Randomization 
One (1) breast per subject will undergo study-specific procedures (hereafter referred to as “breast of interest”) 
while the second breast will be imaged per standard of care. The breast of interest will be randomized across all 
subjects so that approximately half the subjects will be assigned to the first imaged breast and the other half will 
be assigned to the second imaged breast (Figure 2).  
Site technologists conducting the study will perform each subject’s mammography exam per standard practice. 
Thus, the laterality of the breast of interest will solely depend on which breast (left or right) the technologist 
images first and second in standard practice. 
Breast of 
Interest = 1st 
(n =18)
1st Breast
Patient-assisted 
compression, with only 
one (1) two-view (CC & 
MLO) image acquisition.
1st Breast 
Technologist-controlled 
compression, per 
standard of care
2nd Breast 
Image acquisition, 
including compression, 
per standard of care.
Breast of 
Interest = 2nd  
(n =18)
1st Breast 
Image acquisition, 
including compression, 
per standard of care.
2nd Breast 
Patient-assisted 
compression, with only 
one (1) two-view (CC & 
MLO) image acquisition.
2nd Breast 
Technologist-controlled 
compression, per 
standard of care
 
Figure 2 – Schematic showing image acquisitions based on the randomly-assigned breast of interest (i.e. first or second 
breast). 
 Criteria for Withdrawal/Discontinuation 
A subject may withdraw from study participation at any time, for any reason, and the investigator may withdraw 
a subject at any time, for any reason. The reasons for withdrawal and discontinuation for any subject shall be 
recorded on a case report form (CRF) and reported to the Sponsor. The Ethics Committee (EC) should be notified 
per their notification-of-subject-withdrawal policy. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 19 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
A subject shall be withdrawn from the study if a study-related PA compression in either CC or MLO view is not 
completed (i.e. no image is acquired due to inadequate compression or positioning). If a subject withdraws or is 
withdrawn, all efforts will be made to complete and report study data up to the time of withdrawal. A complete 
final evaluation at the time of the subject’s withdrawal shall be made and recorded on a CRF. If the reason for 
withdrawal is related to an adverse event (AE) or serious adverse event (SAE), monitoring of the subject will 
continue until the outcome is evident. 
Any data collected for the subject, up until the time of withdrawal or discontinuation, may still be included in the 
study results and provided to the Sponsor, unless the subject requests that their data not be used. The site shall 
document all requests by subjects regarding their data use. 
5. STUDY PROCEDURES 
 Diagram of Procedures  
Figure 3 shows a high-level sequence of study procedures that will be conducted in this study. 
1st breast (n = 18)
PA compression   
TC compression
2nd breast
SoC
1st  breast (n = 18)
SoC
2nd breast
PA compression   
TC compression
Female adults (≥40 
years) scheduled for 
screening FFDM.
Randomized 
to 1st or 2nd 
breast of 
interest
Consented subjects 
meeting study eligibility 
criteria.
(N ≤ 36)
End subject 
participation
Reader image evaluation 
(N = 30 complete & 
evaluable subjects)
 
Figure 3 – Diagram of study procedures. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 20 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
 Subject Preparation 
Study staff will confirm that the subject is eligible and willing to comply with applicable site requirements prior to 
starting study procedures. Demographic information, clinical history data, and pregnancy/menopausal status 
will be collected prior to the mammography exam. 
No preparation for the breast imaging exam beyond that usually required by the investigational site is needed 
before procedures. After consenting, however, the study staff will show the subjects how to use the PA 
compression mode prior to starting the exam. 
 Description of Study Procedures 
 Image acquisitions 
Each subject will undergo her regularly scheduled FFDM imaging exam per standard practices at the 
investigational site, with the exception of the study-specific image acquisitions using PA compression. For the 
breast of interest, PA compression and image acquisition will be conducted first and consist of both CC and MLO 
views. There shall be no repeat imaging administered using PA compression mode. Following two-view PA 
compression image acquisition, TC compression and standard of care imaging will be conducted on the same 
breast/breast of interest. Standard of care will be used for imaging of the subject’s other breast.  
A minimum of three (3) site technologists will perform the image acquisitions and related study procedures. Study 
procedures shall not impact the order in which the left and right breasts are imaged during the subjects’ exams. 
There will be two (2) study-specific image sets of the breast of interest for each subject. Image sets will consist of 
CC and MLO views obtained using PA compression and CC and MLO views obtained using TC compression.  
5.3.1.1 Image set acquisition time
Study staff will capture the following times associated with the study procedures: 
1) Amount of time it took to educate the subject on the PA compression mode and remote control. 
2) Start time of first PA compression on breast of interest. 
3) Start time of first TC compression on breast of interest. 
 Image attribute review 
Following acquisition, study-specific images will be de-identified, and the time stamp, compression force, and 
breast thickness will be removed from the DICOM header to ensure the readers are blinded to the compression 
mode used for each image set. 
PA and TC compression image sets will be evaluated by two (2) MQSA-qualified readers, with a third reader to 
provide adjudication if disagreement is observed between the two (2) readers’ evaluations of “overall clinical 
image quality” (i.e. item number 9 in Section 5.3.2 Image attribute review). Images will be displayed on site-
provided mammography review workstations/systems in the order in which they were acquired from the study 
subjects. Each reader will evaluate each image set independently from other reader(s) and have the freedom to 
navigate between views, as he/she would do in clinical practice.  
In addition to the images, the following case data will be available to the readers for each image set during image 
attribute review: 
• 
Techniques (anode, filter, kVp, mAs, half-value layer)  
• 
Estimated average glandular dose per view (mGy) 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 21 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
 Follow-up 
No follow-up will be conducted in this study. 
6. STUDY DATA COLLECTION AND ASSESSMENTS 
 Image Acquisition Data  
The following data will be collected on a study CRF during the mammography exams: 
1) Date of mammography exam 
2) Demographic information, including age and ethnicity 
3) Menopausal status 
4) Size of paddle used for imaging (per breast) – 24 x 29.8 cm or 19 x 23 cm 
5) Time to educate patient of PA compression – 1-2 minutes, 3-5 minutes, or more than 5 minutes 
6) Breast of interest – First breast imaged or Second breast imaged 
7) Laterality of the breast of interest – Right or Left 
8) Start time of first PA compression on breast of interest (hh:mm) 1 
9) Start time of first TC compression on breast of interest (hh:mm) 1 
When a subject’s mammography exam is complete, the following data will be collected on a study CRF: 
1) Considering the PA compression only, did the technologist intervene while the subject was controlling 
the compression? Yes or No. If yes, please indicate which of the following interventions were done: 
a. Use footswitch to increase compression 
b. Used footswitch to decrease compression 
c. 
Used manual knobs to increase compression 
d. Used manual knobs to decrease compression 
2) Considering the PA compression only, would you have repeated the image acquisition? Yes or No. If yes, 
please select the option below that best describes the reasoning. 
a. Positioning 
b. Compression 
c. 
Other, please explain. 
3) Considering the TC compression only, did you repeat image acquisition? Yes or No. If yes, please select 
the option below that best describes the reasoning. 
a. Positioning 
b. Compression 
c. 
Other, please explain. 
4) Compression force (daN) – obtained from DICOM header 
5) Breast thickness (mm) – obtained from DICOM header 
 
1 End times will be retrieved from the DICOM header of the last image acquired for a given image set. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 22 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
6) AGD (mGy) – obtained from DICOM header 
7) Per-view acquisition parameters (mAs and kVp) – obtained from DICOM header 
 Image Attribute Review Data 
Following training (see Section 7. Qualification and Training Plan), readers will evaluate all image sets from all 
cases by classifying each of the following image attributes as either “Acceptable” or “Not Acceptable” on CRFs. 
1) Breast positioning, assessing coverage of the breast on craniocaudal and mediolateral oblique view, 
separately 
2) Exposure, assessing visualization of the adipose and fibroglandular tissues, and visualization of breast 
tissue underlying the pectoralis muscle, separately 
3) Breast compression, assessing overlapping breast structures, uniformity of exposure of fibroglandular 
tissues, adequacy of penetration of thicker portions of the breast, exposure of thinner areas, and motion 
unsharpness 
4) Image contrast for differentiation of subtle tissue density differences 
5) Sharpness, assessing the edges of fine linear structures, tissue borders, and benign calcifications 
6) Tissue visibility at the skin line 
7) Noise, i.e., noise obscuring breast structures or suggestive of structures not actually present 
8) Artifacts due to image processing, detector failure and other factors external to the breast on hard-copy 
and soft-copy displays 
9) Overall clinical image quality 
a. If you answered “not acceptable” for overall clinical image quality, would you request repeat 
imaging in standard clinical practice? Yes or No.  
b. If yes, which view would you request for repeat imaging?  CC only, MLO only, or both CC and 
MLO? 
If an issue is encountered by any reader during the image attribute review of any image set, an explanation of 
the issue will be documented on a CRF by the reader. 
Readers will also classify the breast density of each image set as follows: 
1) Almost entirely fatty  
2) Scattered areas of fibroglandular density  
3) Heterogeneously dense  
4) Extremely dense  
 Safety Assessments 
The description, severity, and device relatedness of any AE or SAE during the study will be recorded. Subjects will, 
if necessary, be provided with emergency care. In the event of any device issues, the event will be recorded. 
Safety reporting will be conducted as described in this protocol. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 23 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
7. QUALIFICATION AND TRAINING PLAN 
 Staff Qualifications 
All members of the study staff participating in the conduct of the clinical investigation shall be qualified by 
education, training and/or experience to perform their tasks, and this shall be documented appropriately, as per 
ISO 14155:2011. Specifically, readers shall be MQSA-qualified. 
 Training Plan for the Protocol and Research Product 
Before starting the study, study staff will be trained on the requirements and procedures set forth in this study 
protocol, including completion of ICFs, CRFs, and other study documentation. Training will also be provided to 
ensure appropriate storage and handling of data, and all study staff will be required to be trained on Good Clinical 
Practice (GCP) guidelines per ISO 14155: 2011. 
A record of all formal training will be stored in the Site Regulatory Binder and provided to the Sponsor for inclusion 
in the Sponsor’s CHF. Documentation of training will include: 
• 
Title of Training 
• 
Training objectives 
• 
Training logistics (trainer and training methods) 
• 
Documentation of trainees 
• 
Training content (e.g. device operation, protocol review and CRF completion) 
Study staff directly operating the PA compression product will be qualified based on mammographic experience 
and trained to use PA compression by a GE application specialist. 
The Principal Investigator will be ultimately responsible for execution of this study in accordance with the protocol 
and for device use in this study by members of the study staff. 
8. SAFETY 
 Anticipated Adverse Events  
Mammography is an x-ray examination of the breasts. As with all x-ray exams, mammography involves ionizing 
radiation. The amount of radiation from a standard FFDM mammography exam, even with the addition of the 
study-specific unilateral, two-view imaging, is small and equal in cancer risk to the total body radiation received 
naturally from the environment over a period of a few months.  
There are no known additional medical risks or side effects from Senographe Pristina FFDM with PA compression 
mode beyond those of similar conventional clinical procedures on other commercial mammography devices. 
Foreseeable AEs that apply to mammography and are also applicable to digital mammography using the 
Senographe Pristina with PA compression mode may include, but are not limited to: 
• 
Bruising (uncommon); 
• 
Skin irritation (uncommon), abrasions (uncommon), or tears (rare); 
• 
Discomfort (common). 
The study staff conducting the research is trained to recognize these reactions, and should it be necessary, other 
medical care is available at the site. Subjects will be followed for AEs from the time they enter the imaging suite 
for their exam until the time they exit the imaging suite after the exam. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 24 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
It is generally agreed that the risk to a fetus from radiation in a screening mammography exam is minimal 19; 
however, it is standard clinical practice to try to determine pregnancy status of women referred for 
mammography and not allow women known or suspected to be pregnant to undergo screening mammography 
or other elective radiologic procedures. 
There is always a chance of unexpected risks. Throughout the study, the Sponsor will evaluate and update safety 
information in study documents.  
 Adverse Event Definitions 
Adverse Event (AE): any untoward medical occurrence, unintended disease or injury, or untoward clinical signs 
(including abnormal laboratory findings) in subjects, users or other persons, whether or not related to the 
investigational medical device [ISO 14155:2011 3.2]. This includes events related to the investigational device or 
the comparator and to the procedures involved. For users or other persons, this is restricted to events related to 
the investigational medical device. 
Serious Adverse Event (SAE): an adverse event that led to death; led to a serious deterioration in the health of 
the subject, that either resulted in a life-threatening illness or injury, a permanent impairment of a body structure 
or a body function, or in-patient or prolonged hospitalization, or medical or surgical intervention to prevent life-
threatening illness or injury or permanent impairment to body structure or a body function; or led to fetal distress, 
fetal death or a congenital abnormality or birth defect. Planned hospitalization for a pre-existing condition, or a 
procedure required by the protocol without serious deterioration in health, is not considered a SAE [ISO 
14155:2011 3.37]. 
Adverse Device Effect (ADE): an adverse event related to the use of an investigational medical device [ISO 
14155:2011 3.1]. This includes any adverse events resulting from insufficient or inadequate instructions for use, 
deployment, implantation, installation, or operation, or any malfunction of the investigational medical device. 
This includes any event that is a result of a user error or intentional misuse of the investigational device [ISO 
14155:2011 3.43]. 
Serious Adverse Device Effect (SADE): an adverse device effect that has resulted in any of the consequences 
characteristic of a serious adverse event [ISO 14155:2011 3.36]. 
Device deficiency: an inadequacy of a medical device with respect to its identity, quality, durability, reliability, 
safety, or performance, such as malfunctions, use errors, and inadequate labelling [ISO 14155:2011 3.15]. 
Unanticipated serious adverse device effect (USADE): a serious adverse device effect, which by its nature, 
incidence, severity, or outcome has not been identified in the current version of the risk analysis report [ISO 
14155:2011 3.42]. In the United States, any serious adverse effect on health or safety or any life-threatening 
problem or death caused by, or associated with, a device, if that effect, problem, or death was not previously 
identified in nature, severity, or degree of incidence in the study documents, will be reported in accordance with 
21 CFR §812.3 and applicable laws and regulations. 
 Documentation of Safety Events 
All adverse events (AE), including all serious adverse events (SAE), are required to be collected, investigated, and 
documented during the study reporting period, as defined in the study procedure set forth in this protocol. 
Documentation will include: 
• 
Description of Event 
• 
Date of onset and resolution  
• 
Severity (mild, moderate, or severe)  
 
Mild: Symptom(s) barely noticeable to the subject or does not make the subject uncomfortable. 
The AE does not influence performance or functioning. Prescription drugs are not ordinarily 
needed for relief of symptom(s). 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 25 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
 
Moderate: Symptom(s) of a sufficient severity to make the subject uncomfortable. Performance 
of daily activities is influenced. Treatment of symptom(s) may be needed. 
 
Severe: Symptom(s) of a sufficient severity to cause the subject severe discomfort. Treatment 
for symptom(s) may be given. 
• 
Serious (yes/no)  
• 
Causal relationship to investigational medical device? (not related, possibly related, or related) 
 
Not related: The adverse event is reasonably expected to be related to (or caused by) a 
concurrent illness, effect of another device/drug or other cause, and is unlikely related to the 
investigational product. 
 
Possibly related: The adverse event is reasonably expected to be related to the investigational 
product, and an alternative etiology is equally or less likely compared to the potential 
relationship to investigational product. 
 
Related: There is a strong relationship to investigational product or recurs on re-challenge, and 
another etiology is unlikely or there is no other reasonable medical explanation for the event. 
• 
Treatment given and/or action taken (procedure stopped, withdrawn from study, or no action) 
• 
Anticipated (yes/no) 
 Reporting of Safety Events and Device Deficiencies/Complaints 
The following events are to be reported to the Sponsor within 72 hours of the event occurrence and to the EC per 
their policy: 
• 
All SAEs and USADEs 
• 
All device issues that could possible lead to an SAE 
Additional follow-up information may be requested by the Sponsor. In addition, safety information may be shared 
with regulatory agencies and other participating sites, as required by applicable law and regulation. 
If the event resulted in the death of a subject, the event shall also be reported via telephone to the Sponsor within 
24 hours of knowledge of the event. SAEs will be reported to the local EC per their policy. 
Sponsor contact for SAEs and UADEs: 
Ron von Jako, MD, PhD 
Fax: 1-800-888-3983 
E-mail: SAE@ge.com 
 Device Deficiencies/Complaints 
Device deficiencies/complaints should be reported to the study Sponsor contact identified on the cover page of 
this protocol. All device deficiencies/complaints will be collected, fully investigated, and documented in the 
source document and appropriate Sponsor document during the study reporting period. The PI is responsible for 
notifying the Sponsor in the event that there is any device issue that could potentially lead to a SAE. 
9. ETHICAL CONDUCT OF THE STUDY 
The study will be carried out in accordance with the protocol and with principles enunciated in the current version 
of the Declaration of Helsinki; the guidelines of Good Clinical Practice (GCP) for medical devices, as set forth by 
ISO 14155:2011 and ISO 14971:2012; applicable sections of U.S. FDA 21 Code of Federal Regulations (CFR); and 
applicable regulatory authority’s requirements of the U.S. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 26 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
The study will be conducted and reported in accordance with applicable policies of the EC and governing 
regulatory authorities. 
 Ethics Committee 
The PI will ensure that approval from an appropriately constituted EC is attained for the clinical study prior to 
enrolling subjects, and Principal Investigator will ensure that documentation of approval is maintained for the 
duration of the study.  
The PI will ensure that the Sponsor is notified of any withdrawal of EC approval within 5 working days of such 
occurrence. If approval is terminated or suspended, the Principal Investigator will promptly notify the Sponsor 
and provide written explanation. 
 Regulatory Agencies and Competent Authority(ies) 
The Sponsor will obtain approval from the local regulatory agency and competent authority (CA) before the start 
of the clinical trial, if necessary, per applicable local laws and regulations. Any additional requirements imposed 
by the EC or regulatory authority shall be followed, if applicable. 
 Management of Protocol Modifications and Amendments  
Substantial amendments will only be implemented after approval of the EC.  
A deviation is any instance(s) of failure to follow, intentionally or unintentionally, the requirements of the protocol. 
Under emergency circumstances, deviations from the protocol to protect the rights, safety, and wellbeing of 
human subjects may proceed without prior approval of the Sponsor and the EC/competent authority (CA). Such 
deviations shall be documented and reported to the Sponsor and the EC as soon as possible. Deviations will be 
reported as: 
• 
Critical Deviations: Deviations that significantly affect the safety, efficacy, integrity, or conduct of the 
study. These deviations must be reported to the Sponsor no later than 5 working days from awareness 
of occurrence and reported to the EC per the deviation reporting policy.  
• 
Non-Critical Deviations: Protocol deviations that do not significantly affect the safety, efficacy, integrity, 
or conduct of the trial. These deviations must be documented on the CRF Protocol Deviation page and 
will be reviewed by the study monitor. 
Non-substantial modifications may be made during the normal course of device optimization, maintenance, and 
feasibility testing. Non-substantial modifications will be communicated to the CA as soon as possible, if 
applicable, and to the EC per their policy.  
 Participant Information and Informed Consent  
The investigators will explain to each participant the nature of the study, its purpose, the procedures involved, 
the expected duration of exposure to the investigational product (if applicable), the potential risks and benefits, 
and any potential discomforts. Each participant will be informed that participation in the study is voluntary, that 
she may withdraw from the study at any time, and that withdrawal of consent will not affect her subsequent 
medical assistance and treatment. The participant must be informed that her medical records may be examined 
by authorized individuals other than their treating physician. 
All participants for the study will be provided an ICF, describing the study and providing sufficient information to 
allow the participant to make an informed decision about her participation in the study. Informed consent 
documents will be subject to approval by the EC prior to enrolling subjects in the study. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 27 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
The participant should read and consider the statement before signing and dating the ICF, and shall be given a 
copy of the signed document. The ICF must also be signed and dated by the PI (or his/her designee), and it shall 
be retained as part of the study records. 
 Early Termination of the Study 
The Sponsor may terminate the study prematurely according to certain circumstances. Examples of such 
circumstances include ethical concerns, insufficient participant recruitment, participant safety concerns, 
alterations in accepted clinical practice that make the continuation of a clinical trial unwise, early evidence of 
benefit or harm of the research product, or for any other reason. 
10. 
STATISTICAL METHODS 
 Statistical Hypothesis  
No statistical hypothesis is being tested in this study. 
 Sample Size Determination 
The target sample size for this study is 30 subjects, providing 60 evaluable image sets for the image attribute 
review (30 PA compression image sets and 30 TC compression image sets). The number of subjects was 
determined based on Sponsor discussions with a U.S. FDA Medical Officer, who indicated that, during MQSA re-
accreditation, sites are requested to submit sample images. If an issue is identified with the sample images, an 
Advanced Mammographic Review occurs, where the quality of 30 images is assessed to determine whether the 
issue was isolated or systemic.  
With a sample size of 30 image pairs, the 95% confidence interval width for the proportion of PA image sets with 
equal or higher acceptability than TC image sets will be no wider than 13%, when the proportion is 95%. 
 Statistical Analysis 
 General Statistical Methods 
The study data will be summarized using descriptive statistics. The descriptive statistics for continuous variables 
will include mean, standard deviation, median, Q1 and Q3, minimum, maximum, and sample size, as appropriate. 
Categorical variables will be described with counts, percentages, and sample size, as appropriate. A 95% 
confidence interval may be presented, when necessary. 
 Analysis of Primary Endpoint 
The proportion of PA image sets that are of equal or higher acceptability than TC image sets will be calculated.  
A 95% confidence interval will be calculated using asymptotic method with continuity correction. This analysis 
will also be performed for subgroups defined by the randomized breast of interest (i.e. breast of interest imaged 
first versus breast of interest imaged second). 
Proportion of images with acceptable overall image quality will be summarized for PA image sets and TC image 
sets separately, with 95% confidence interval using asymptotic method with continuity correction. 
 Analysis of Secondary and Exploratory Endpoints 
The proportion of image sets indicated for repeated image acquisition when using PA mode or TC mode will be 
summarized. This analysis will also be performed for subgroups defined by the randomized breast of interest. 
The acceptability for individual mammographic attributes will be summarized by attribute.  

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 28 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
Time to complete image acquisition for PA mode and TC mode will be summarized descriptively. Type and 
number of technologist intervention needed during PA mode will be summarized. Similarly, patient 
characteristics (demographics, breast thickness) and procedural characteristics (radiation dose, compression 
force) will be summarized using descriptive statistics. 
Compression force analysis will also be performed for subgroups defined by the randomized breast of interest. 
 Safety Analysis  
AEs, SAEs, and devices issues will be provided in listings and will be summarized descriptively, as deemed 
necessary.  
10.3. Interim Analysis 
No interim analyses are intended to be conducted as part of this study. 
 Handling of Missing Data  
Analysis will be based on collected data, and no imputation will be done for missing data. 
 Deviation(s) from the Original Statistical Methods 
Any changes or deviations from the original statistical plan specified in this protocol will be described and justified 
in the final study report per ISO 14155:2011. 
11. 
 QUALITY ASSURANCE AND CONTROL 
Data Management
Data management processes for handling study data will be maintained by the Sponsor. 
 Completion of Case Report Forms (CRFs) 
The data reported on the CRFs shall be derived from source documents and be consistent with these source 
documents. Paper CRFs and/or electronic CRFs (eCRFs) will be used to collect data. The Sponsor will provide 
e/CRFs and train study staff on completion of e/CRFs using Good Documentation Practices (GDP). CRF Completion 
Guidelines (CCG) may be provided by the Sponsor to help facilitate training. 
e/CRFs are to be completed as information becomes available at the site. e/CRFs should be signed by indicated 
parties, in indicated area(s), to certify the contents of the form. The Principal Investigator is ultimately responsible 
for ensuring completion of e/CRFs. 
If discrepancies are discovered on paper CRFs during monitoring, the Sponsor’s representative will ensure that 
the study staff makes necessary corrections directly to the CRF(s) prior to collection.  
Following CRF collection, the Sponsor will review the data. A Data Clarification Form (DCF) may be provided to 
the site to correct or clarify discrepancies. 
If a site discovers discrepancies after CRF collection, the site may notify the Sponsor and request data 
modification.  
If discrepancies are discovered on the eCRF, whether during monitoring or during data review by the study team, 
a query will be raised, and the site shall make the correction within the electronic database, noting the reason 
for change. Data will be considered clean once all queries are answered and closed.  
If the Sponsor discovers discrepancies on eCRFs, a query will be raised and necessary corrections will be made 
by the site. The reason for any changes will be noted. All queries will be resolved prior to study completion. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 29 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
 Data Handling and Record Keeping  
All documents and data shall be produced and maintained in a manner that assures control and traceability. 
 Source Data and Documents 
Source data includes information in original records, certified copies of original records of clinical findings, 
observations, or other activities for the study. Source documents for each subject must be retained throughout 
the investigation, including printed or electronic documents containing source data. Elements should include: 
• 
Source data and documentation relevant to data recorded for subject screening and CRF 
corroboration. 
• 
Subject records containing the completed ICFs and CRFs. 
• 
Regulatory binder containing the protocol and any subsequent amendments, EC submissions and 
approvals, blank ICF(s), and site logs. 
• 
Reference manuals such as investigator responsibilities, Sponsor, AE/SAE and informed consent 
guidelines, applicable training materials, and operator manual for PA compression. 
The Principal Investigator or institution shall provide direct access to source data during and after the clinical 
investigation for monitoring, audits, EC review, and regulatory authority inspections.  
 Archiving 
All study data must be archived for a minimum of three (3) years after study termination or premature termination 
of the clinical trial. No source documents or study records will be destroyed without Sponsor notification and 
approval. 
12. 
MONITORING PLAN  
In collaboration with the site, the Sponsor will ensure proper monitoring of the study to confirm that all the 
research requirements are met. Monitoring visits will oversee the progress of a clinical investigation and ensure 
that it is conducted, recorded, and reported in accordance with the protocol, written procedures, Good Clinical 
Practice (GCP) ISO 14155:2011, and the applicable regulatory requirements. 
 Confidentiality and Data Protection 
The investigator affirms and upholds the principle of the participant's right to privacy, and the investigator shall 
comply with applicable privacy laws. Especially, anonymity of the participants shall be guaranteed when 
presenting the data at scientific meetings or publishing data in scientific journals. 
Individual subject medical information obtained as a result of this study will be considered confidential, and 
disclosure to third parties will be prohibited. Subject confidentiality will be further ensured by utilizing subject 
identification code numbers. For data verification purposes, authorized representatives of the Sponsor, a 
competent authority (CA), or an ethics committee (EC) may require direct access to parts of the medical records 
relevant to the study, including subject medical history. 
 Storage of Images and Associated Health Data 
Images and associated data will be collected and disclosed to the Sponsor as part of this study. Fully de-identified 
data, which has had all personal identifying information removed, may be stored and used by the Sponsor 
indefinitely. The Sponsor and/or its authorized representatives may use any de-identified data collected in this 
study for future technology and engineering development, marketing purposes, education, regulatory 
submissions, publications, or other possible uses. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
Page 30 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
 Publication Policy 
The results of this study may be used in future publications. If applicable, the conditions of publication shall be 
described in a separate contractual agreement. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
 
 
Page 31 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
REFERENCES 
1. ISO. Clinical investigation of medical devices for human subjects - Good Clinical Practice: International 
Organization for Standardization; 2011. ISO 14155:2011(E). 
2. American Cancer Society. Breast Cancer Facts & Figures 2015-2016. United States: American Cancer Society; 
2015. 
3. American Cancer Society. Global Cancer Facts & Figures 3rd Edition. Atlanta: American Cancer Society; 2015. 
4. Nelson HD, Cantor A, Humphrey L, et al. Screening for Breast Cancer: A Systematic Review to Update the 2009 
U.S. Preventive Services Task Force Recommendation. Rockville: Agency for Healthcare Research and Quality; 
2016. 14-05201-EF-1. 
5. Shapiro S, Strax P, Venet L. Periodic breast cancer screening in reducing mortality from breast cancer. JAMA. 
1971;215(11):1777-1785. 
6. Thurfjell E, Lendgren J. Breast cancer survival rates with mammographic screening: similar favorable 
survival rates for women younger and those older than 50 years. Radiology. 1996;201(2). 
7. Hendrick R, Smith R, Rutledge J, Smart C. Benefit of screening mammography in women aged 40-49: a new 
meta-analysis of randomized controlled trials. J Natl Cancer Inst Monogr. 1997;22:87-92. 
8. Tabar L, Vitak B, Chen H, Yen M, Duffy S, Smith R. Beyond randomized controlled trials: organized 
mammographic screening substantially reduces breast carcinoma mortality. Cancer. 2001;91(9):1724-1731. 
9. The Swedish Organized Service Screening Evaluation Group. Reduction in breast cancer mortality from 
organized service screening with mammography: 1. Further confirmation with extended data. Cancer 
Epidemiol. 2006;15(1):45-51. 
10. Coldman A, Phillips N, Wilson C, et al. Pan-Canadian Study of Mammography Screening and Mortality. 
Journal of the National Cancer Institute. Oct 2014;106(11):1-7. 
11. Hofvind S, Ursin G, Tretli S, Sebuødegård S, Møller B. Breast cancer mortality in participants of the Norwegian 
Breast Cancer Screening Program. Cancer. Sep 2013;119(17):3106-3112. 
12. Whelehan P, Evans A, Wells M, Macgillivray S. The effect of mammography pain on repeat participation in 
breast cancer screening: a systematic review. Breast. Aug 2013;22(4):389-394. 
13. Dullum JR, Lewis EC, Mayer JA. Rates and correlates of discomfort associated with mammography. 
Radiology. Feb 2000;214(2):547-552. 
14. Gupta R, Nayak M, Khoursheed M, Roy S, Behbehani AI. Pain during mammography: impact of breast 
pathologies and demographic factors. Medical principles and practice. Jul-Sep 2003;12(3):180-183. 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
 
 
Page 32 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
15. Poulos A, Rickard M. Compression in mammography and the perception of discomfort. Australasian 
Radiology. Aug 1997;41(3):247-252. 
16. Kornguth PJ, Rimer BK, Conaway MR, et al. Impact of patient-controlled compression on the mammography 
experience. Radiology. Jan 1993;186(1):99-102. 
17. de Groot JE, Broeders MJ, Brandenhorst W, den Heeten GJ, Grimbergen CA. Mammographic compression 
after breast conserving therapy: controlling pressure instead of force. Medical Physics. Feb 2014;41(2). 
18. de Groot JE, Branderhorst W, Grimbergen CA, den Heeten GJ, Broeders MJM. Towards personalized 
compression in mammography: A comparison study between pressure- and force-standardization. 
Euorpean Journal of Radiology. Mar 2015;84(3):384-391. 
19. Sechopoulos I, Suryanarayanan S, Vedantham S, D'Orsi C, Karellas A. Radiation Dose to Organs and Tissues 
from Mammography: Monte Carlo and Phantom Study. Radiology. 2008;246:434-443. 
 
 
 
 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
 
 
Page 33 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
APPENDIX A – STUDY SCHEDULE 
Table A.1 - Schedule of Study Procedures 
Evaluation 
 
Subject Visits* 
Post Image Acquisition 
Screening & Enrollment** 
Visit 1** 
Written Informed Consent 
X 
 
 
Patient Demographics 
X 
 
 
Inclusion criteria 
X 
 
 
Exclusion criteria 
X 
 
 
FFDM Exam, including 
patient-assisted 
compression for the breast 
of interest 
 
X 
 
Image acquisition data 
collection 
 
X 
 
Image attribute review 
 
 
X 
*Subjects will be followed for AE reporting purposes from the time when they enter the imaging exam room until the time 
when they leave the imaging exam room at each visit. There will be no follow-up. 
** Screening, enrollment, and procedures may be conducted on the same day for study subjects. 
 
 

Study Title: Patient-Assisted Compression – Impact on Image Quality and Workflow 
Study No: 124.03-2017-GES-0002 
 
 
Page 34 of 34 
 
GE MWS DOC1991348 
 
 
Ver: 1.0; 22/May/2017 
GE Healthcare - Confidential 
APPENDIX B – STUDY SITE AND INVESTIGATOR LIST  
The following investigators at each study site will be responsible for the conduct of this study:  
Investigator(s):1 
 
Kathy Schilling, MD, Principal 
Investigator 
Tel:  
1-561-955-5000 
e-mail:  
kschilling@brrh.com 
Boca Raton Regional Hospital 
Christine E. Lynn Women’s Health and 
Wellness Institute 
Address: 690 Meadows Road 
 
Boca Raton, FL, 33486 U.S. 
1 The role of the Principal Investigator is to implement and manage the conduct of the investigation as well as ensure data 
integrity and the rights, safety, and well-being of humans involved in the study [ISO 14155:2011 9.1]. Co-Investigators share 
all responsibilities of the Principal Investigator, and Sub-investigators share only those responsibilities designated by the 
Principal Investigator.